Published in Br J Clin Pharmacol on January 01, 2011
Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy (2012) 1.04
Management of cutaneous disorders related to inflammatory bowel disease. Ann Gastroenterol (2012) 0.84
Infliximab dose reduction sustains the clinical treatment effect in active HLAB27 positive ankylosing spondylitis: a two-year pilot study. Mediators Inflamm (2013) 0.80
Tumor necrosis factor antagonists in the treatment of multicentric reticulohistiocytosis: Current clinical evidence. Mol Med Rep (2016) 0.75
Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum (1995) 26.94
Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum (1984) 20.51
Unravelling the pathogenesis of inflammatory bowel disease. Nature (2007) 18.52
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Pathogenesis and therapy of psoriasis. Nature (2007) 6.94
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut (2010) 4.50
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut (2008) 4.41
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol (2006) 4.18
Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med (2006) 4.12
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet (2005) 3.59
Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology (Oxford) (2005) 3.56
The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 3.50
Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum (2006) 3.26
Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet (2001) 3.19
British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol (2005) 3.10
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum (2002) 2.96
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.65
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol (1993) 2.47
Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol (2003) 2.30
First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis (2005) 2.21
Guidelines for treatment with infliximab for Crohn's disease. Neth J Med (2006) 2.10
The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol (2003) 2.06
Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology (2005) 2.05
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology (Oxford) (2005) 1.66
Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol (2002) 1.63
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006. Gastroenterology (2007) 1.60
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther (2009) 1.58
Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology (Oxford) (2006) 1.57
Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit (2008) 1.42
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis (2007) 1.37
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet (2007) 1.31
Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions. J Am Acad Dermatol (2000) 1.24
Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis. Mod Rheumatol (2007) 1.21
Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine (2007) 1.01
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis (2007) 0.99
Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine (2007) 0.96
Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol (2004) 0.95
Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systematic review. Arthritis Rheum (2008) 0.93
Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. Ann Rheum Dis (2008) 0.93
Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol (2004) 0.85
Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology (2008) 0.78
Monitoring vital signs during infusion with infliximab does neither indicate nor predict development of acute infusion reactions. J Clin Gastroenterol (2009) 0.76
Genome-wide association identifies multiple ulcerative colitis susceptibility loci. Nat Genet (2010) 4.65
Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2. Gut (2011) 2.91
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol (2007) 2.73
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol (2005) 2.52
A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum (2007) 2.36
Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology (2009) 2.33
NOD2 and toll-like receptors are nonredundant recognition systems of Mycobacterium tuberculosis. PLoS Pathog (2005) 2.04
Neoplasia yield and colonoscopic workload of surveillance regimes for colorectal cancer in colitis patients: a retrospective study comparing the performance of the updated AGA and BSG guidelines. Inflamm Bowel Dis (2013) 1.96
NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol (2004) 1.90
Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther (2005) 1.85
Analysis of SNPs with an effect on gene expression identifies UBE2L3 and BCL3 as potential new risk genes for Crohn's disease. Hum Mol Genet (2010) 1.78
Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut (2011) 1.74
Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2012) 1.64
Current and future treatment options for acne. J Dermatolog Treat (2006) 1.60
Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol (2010) 1.58
A functional polymorphism in UGT1A1 related to hyperbilirubinemia is associated with a decreased risk for Crohn's disease. J Crohns Colitis (2011) 1.54
Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha. J Rheumatol (2008) 1.52
Safety of infliximab in inflammatory bowel disease needs to be debated. Clin Gastroenterol Hepatol (2008) 1.38
Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci (2013) 1.38
Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol (2013) 1.35
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis (2013) 1.31
Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Ann Rheum Dis (2012) 1.30
The frameshift mutation in Nod2 results in unresponsiveness not only to Nod2- but also Nod1-activating peptidoglycan agonists. J Biol Chem (2005) 1.28
Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis (2005) 1.24
Mycobacterium paratuberculosis is recognized by Toll-like receptors and NOD2. J Leukoc Biol (2007) 1.22
Impaired dendritic cell function in Crohn's disease patients with NOD2 3020insC mutation. J Leukoc Biol (2006) 1.22
Validation study of existing gene expression signatures for anti-TNF treatment in patients with rheumatoid arthritis. PLoS One (2012) 1.19
Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology (2007) 1.12
[Quality indicators for colonoscopy: differences in polyp detection between endoscopists at one hospital]. Ned Tijdschr Geneeskd (2012) 1.08
Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One (2009) 1.06
The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) (2012) 1.06
Carbohydrate antigen 19-9 is extremely elevated in polycystic liver disease. Liver Int (2009) 1.05
Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry. BMC Musculoskelet Disord (2013) 1.04
Recognition of Borrelia burgdorferi by NOD2 is central for the induction of an inflammatory reaction. J Infect Dis (2010) 1.04
Self-reported disability in patients with inflammatory bowel disease largely determined by disease activity and illness perceptions. Inflamm Bowel Dis (2015) 1.04
False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer (2009) 1.03
Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut (2013) 1.02
Scleredema diabeticorum case series: successful treatment with UV-A1. Arch Dermatol (2008) 1.01
How to improve DAS28 use in daily clinical practice?--a pilot study of a nurse-led intervention. Rheumatology (Oxford) (2010) 1.00
Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys (2006) 0.99
Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review. World J Gastroenterol (2013) 0.99
Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart (2012) 0.98
Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis (2012) 0.96
HNF4α and CDH1 are associated with ulcerative colitis in a Dutch cohort. Inflamm Bowel Dis (2010) 0.95
Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor delta. Pharmacogenet Genomics (2006) 0.95
Experimental stress in inflammatory rheumatic diseases: a review of psychophysiological stress responses. Arthritis Res Ther (2010) 0.94
Farnesoid X receptor (FXR) activation and FXR genetic variation in inflammatory bowel disease. PLoS One (2011) 0.94
Malignant transformation of perianal and enterocutaneous fistulas is rare: results of 17 years of follow-up from The Netherlands. Scand J Gastroenterol (2011) 0.94
Effect of childbirth on the course of Crohn's disease; results from a retrospective cohort study in the Netherlands. BMC Gastroenterol (2011) 0.94
Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol (2007) 0.93
Design and analysis of a randomized controlled trial testing the effects of clinical decision support on the management of rheumatoid arthritis. Arthritis Rheum (2004) 0.93
Cyclooxygenase-2 polymorphisms and the risk of esophageal adeno- or squamous cell carcinoma. World J Gastroenterol (2009) 0.93
Genetic variants in toll-like receptors are not associated with rheumatoid arthritis susceptibility or anti-tumour necrosis factor treatment outcome. PLoS One (2010) 0.93
Differential Toll-like receptor recognition and induction of cytokine profile by Bifidobacterium breve and Lactobacillus strains of probiotics. Clin Vaccine Immunol (2011) 0.92
Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol (2010) 0.92
Treatment strategies aiming at remission in early rheumatoid arthritis patients: starting with methotrexate monotherapy is cost-effective. Rheumatology (Oxford) (2011) 0.92
HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritis. Arthritis Rheum (2008) 0.92
Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol (2009) 0.92
The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol (2009) 0.92
Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia. Inflamm Bowel Dis (2010) 0.92
Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer (2011) 0.91
Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk. Am J Gastroenterol (2009) 0.91
Physical burden of symptoms in patients with localized scleroderma and eosinophilic fasciitis. Arch Dermatol (2008) 0.91
Genetic association analysis of the functional c.714T>G polymorphism and mucosal expression of dectin-1 in inflammatory bowel disease. PLoS One (2009) 0.91
Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int (2007) 0.91
Genetic polymorphisms in GSTA1, GSTP1, GSTT1, and GSTM1 and gastric cancer risk in a Vietnamese population. Oncol Res (2010) 0.90
Clinical factors and the decision to transfuse chronic dialysis patients. Clin J Am Soc Nephrol (2013) 0.90
Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients. Toxicol Lett (2013) 0.90
Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf (2010) 0.89
Respiratory syncytial virus infection augments NOD2 signaling in an IFN-β-dependent manner in human primary cells. Eur J Immunol (2012) 0.89
Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands. Drug Saf (2008) 0.89
Psychological distress in patients with morphea and eosinophilic fasciitis. Arch Dermatol (2009) 0.88
What patients think about E-health: patients' perspective on internet-based cognitive behavioral treatment for patients with rheumatoid arthritis and psoriasis. Clin Rheumatol (2013) 0.88
Biopsychosocial mechanisms of chronic itch in patients with skin diseases: a review. Acta Derm Venereol (2008) 0.88
Evaluating health-related quality of life in patients with polycystic liver disease and determining the impact of symptoms and liver volume. Liver Int (2014) 0.87
Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum (2003) 0.87
Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis. J Rheumatol (2011) 0.87
Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. J Rheumatol (2007) 0.87
Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. Inflamm Bowel Dis (2011) 0.87
Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol (2008) 0.86
Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety. Drugs Aging (2009) 0.86
Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis. Arthritis Res Ther (2013) 0.85
6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol (2003) 0.85
Effectiveness of a multidisciplinary itch-coping training programme in adults with atopic dermatitis. Acta Derm Venereol (2009) 0.85
Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology (Oxford) (2013) 0.84
Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther (2009) 0.84
No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: a study in 3 independent European cohorts. Inflamm Bowel Dis (2008) 0.84
Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. Am J Clin Dermatol (2009) 0.84
Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today (2006) 0.83
Absence of association between the multidrug resistance (MDR1) gene and inflammatory bowel disease. Scand J Gastroenterol (2006) 0.83
Adenomas in patients with inflammatory bowel disease are associated with an increased risk of advanced neoplasia. Inflamm Bowel Dis (2013) 0.83